A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT06934044 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Cevostamab
DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche